For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Standard BioTools Inc (NASDAQ: LAB) closed at $1.28 down -1.54% from its previous closing price of $1.3. In other words, the price has decreased by -$1.54 from its previous closing price. On the day, 0.69 million shares were traded. LAB stock price reached its highest trading level at $1.31 during the session, while it also had its lowest trading level at $1.27.
Ratios:
For a deeper understanding of Standard BioTools Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.37 and its Current Ratio is at 6.12. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 16, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $3.50.
On April 04, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $3.25.Jefferies initiated its Buy rating on April 04, 2024, with a $3.25 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 23 ’25 when Kim Hanjoon Alex sold 1,428 shares for $0.94 per share. The transaction valued at 1,344 led to the insider holds 930,286 shares of the business.
Mackay Sean sold 13,217 shares of LAB for $12,437 on May 23 ’25. The SVP & Chief Business Officer now owns 843,076 shares after completing the transaction at $0.94 per share. On May 23 ’25, another insider, Egholm Michael, who serves as the President & CEO of the company, sold 5,473 shares for $0.94 each. As a result, the insider received 5,150 and left with 2,741,191 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 469615360 and an Enterprise Value of 181311552. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.87 while its Price-to-Book (P/B) ratio in mrq is 1.07. Its current Enterprise Value per Revenue stands at 1.069 whereas that against EBITDA is -1.641.
Stock Price History:
The Beta on a monthly basis for LAB is 1.29, which has changed by -0.2335329 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, LAB has reached a high of $2.32, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is 5.14%, while the 200-Day Moving Average is calculated to be -10.02%.
Shares Statistics:
For the past three months, LAB has traded an average of 1.91M shares per day and 1212360 over the past ten days. A total of 379.09M shares are outstanding, with a floating share count of 367.66M. Insiders hold about 3.20% of the company’s shares, while institutions hold 73.70% stake in the company. Shares short for LAB as of 1752537600 were 12335128 with a Short Ratio of 6.45, compared to 1749772800 on 16159588. Therefore, it implies a Short% of Shares Outstanding of 12335128 and a Short% of Float of 5.53.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
